Product image of Ivabradine Sandoz (Ivabradine Oxalate) supplied by GNH India

Ivabradine Sandoz

Active Ingredient:
Ivabradine Oxalate
Origin:
EU

Ivabradine Sandoz (Ivabradine Oxalate)

Ivabradine, the active ingredient in Ivabradine Sandoz, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH India supplies Ivabradine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Manufacturer / TM Owner

Sandoz

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradine is used to manage conditions where reduction of heart rate improves clinical outcomes, primarily within the cardiovascular disease spectrum.

  • Chronic stable angina pectoris: lowers heart rate to reduce the frequency of angina episodes and improve exercise tolerance.
  • Heart failure with reduced ejection fraction (NYHA class II–III): decreases heart rate, which can improve symptoms and reduce the risk of hospitalization.

How It Works

  • Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which controls spontaneous depolarisation. By blocking this inward sodium/potassium mixed current, the drug slows the pacemaker activity without affecting myocardial contractility, resulting in a controlled reduction of heart rate while preserving cardiac output.

Side Effects

Ivabradine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Visual disturbances (phosphenes): transient luminous phenomena.
  • Bradycardia: resting heart rate below 50 bpm.
  • Headache.
  • Dizziness or light‑headedness.
  • Fatigue.
  • Blurred vision.

Serious or Rare Side Effects

  • Symptomatic bradycardia requiring medical intervention.
  • Atrial fibrillation or other significant arrhythmias.
  • Severe hypotension.
  • Persistent visual impairment.
  • Allergic reactions such as rash or angioedema.

Precautions & Warnings

When prescribing Ivabradine, clinicians should consider several safety and monitoring measures to minimize risk.

  • Heart rate monitoring: obtain baseline resting heart rate and ensure it remains above 60 bpm before initiation.
  • Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or calcium‑channel blockers.
  • Severe hepatic impairment: use with caution or avoid as drug exposure may increase.
  • Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies potential risk.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Ivabradine can interact with other medicines, altering its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Ivabradine exposure.
  • Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive bradycardia.
  • Certain anti‑arrhythmic agents (e.g., amiodarone): additive effect on cardiac conduction.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
  • Antihypertensive agents: monitor blood pressure and heart rate.
  • Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.

Frequently Asked Questions

Ivabradine Sandoz is prescribed for chronic stable angina pectoris and for heart failure with reduced ejection fraction (NYHA class II–III). In both cases the drug works by lowering heart rate, which helps relieve angina symptoms and can improve functional status in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the natural pacemaker of the heart. By inhibiting this mixed sodium‑potassium inward current, the spontaneous depolarisation rate slows, producing a controlled reduction in heart rate without compromising myocardial contractility.

The specific dose and titration schedule are determined by the prescribing clinician based on the patient’s clinical condition, baseline heart rate, and response to therapy. Ivabradine is only available by prescription, and dosing should follow the healthcare professional’s guidance.

Safety data for ivabradine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s overall condition.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and light, and ensure the packaging remains tightly closed until use.

Ivabradine Sandoz is taken orally, usually with a glass of water. The tablets should be swallowed whole and not crushed or chewed. Dosing times are typically aligned with the patient’s daily routine, and the medication may be taken with or without food as directed by the prescriber.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may be persistent. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine should be avoided in patients with a resting heart rate below 60 bpm, those with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine Oxalate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT